The death count increased to 1,54,703 with 107 daily new fatalities, the data showed. (File)
New Delhi:
Over 21 per cent of the population, aged 10 years and above, showed evidence of past exposure to COVID-19 in the ICMR’s latest national serosurvey, the government said on Thursday, noting that a large proportion of people are still vulnerable to the infection.
The Indian Council of Medical Research (ICMR) third national serosurvey was conducted between December 7 last year and January 8.
Presenting the findings of the survey, ICMR Director General Dr Balram Bhargava said 21.4 per cent of the 28,589 people, aged 18 years and above, surveyed during the period showed evidence of past exposure to the coronavirus infection. While 25.3 per cent of children aged 10 to 17 years from the same number of surveyed population have had the disease, he said.
India’s COVID-19 tally of cases rose to 1,07,90,183 with 12,899 new infections being reported in a day, while the recoveries surged to 1,04,80,455, according to the Union Health Ministry data updated on Thursday.
The death count increased to 1,54,703 with 107 daily new fatalities, the data showed.
The number of people who have recuperated from the disease surged to 1,04,80,455 pushing the national COVID-19 recovery rate of 97.13 per cent, while the COVID-19 case fatality rate stands at 1.43 per cent. The total COVID-19 active cases remained below 2 lakh.
Here are the Latest News Live Updates:
Johnson & Johnson Requests Emergency Authorisation For Covid Vaccine
Pharmaceuticals giant Johnson & Johnson on Thursday submitted an application for emergency authorization of its Covid-19 vaccine with US health authorities, the company said in a statement.
The process could take several weeks, but at the end of it the vaccine would be the third authorized in the United States, after those of Pfizer-BioNTech and Moderna.
J&J subsidiary Janssen Biotech “has submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate,” the statement read.
The new vaccine is highly anticipated because it has two big logistical advantages: it can be stored at refrigerator temperatures rather than in special freezers, significantly easing distribution; and it requires just one dose.
